Analyses from CV and kidney outcome trials have demonstrated that the relative benefits of SGLT2 inhibitors are consistent across many patient subgroups including those with or without type 2 diabetes, severity of kidney disease or the presence of heart failure [12, 13]. Here, SLC5A2 is linked to heart failure.